Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Acute myeloid leukemia
Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.
AACR Annual Meeting 2026
17–22 Apr 2026, San Diego · Cancer Research 86 (7_Supplement)
All 7,489 abstracts, including clinical trial (CT) and late-breaking (LB) abstracts, have Cancer Research supplement DOIs in Crossref.
Indexed in Crossref
97 abstracts matching acute myeloid leukemia from the meeting's journal supplement, fetched live from Crossref 2026-11-12 08:35 UTC. This is a keyword search, not the complete abstract book.
- 5429
- 825Bone marrow from acute myeloid leukemia (AML) and multiple myeloma (MM) patients can be used to evaluate target expression and on-target efficacy for novel antibody drug conjugates (ADCs).Aisha Mergaert, Coranna Akdemirbey, Mariah Suchan, Tara Murray et al.
- 5364Neutrophilic skin infiltrates in patients with acute myeloid leukemia (AML) are clonal and associate with poor overall survival.Gabby Tesfaye, Yazan Abu-Shihab, Deedra Nicolet, Jill Buss et al.
- 7892Multi-ancestry genome-wide association study (GWAS) of pediatric acute myeloid leukemia (AML) risk identifies four risk lociCindy Im, Lauren J. Mills, Peggy Meng, Marijana Vujkovic et al.
- 692Novel single cell and bulk NGS assays for improved assessment of MRD (measurable residual disease) and clonal dynamics in acute myeloid leukemia (AML).Crystal Zhou, Ruwan Gunaratne, Emily Yang, Rachel Agoglia et al.
- 7246Transcriptional control of myeloid differentiation trajectories in AMLSagarajit Mohanty, Jieun Jeong, Soumya Sharma, Daniel Cizin et al.
- 2486Racial differences in clinical and cytogenetic features of pediatric acute myeloid leukemiaSara Elbanna, Hassan Mohammed Abushukair
- 3257Improved Variantplex workflow reduces assay time and enhances sensitivity for acute myeloid leukemia targetsDavid Knupp, Michael Washburn
- 7890Insights into chemotherapy-related cognitive impairment in childhood acute myeloid leukemia survivorsJoel Costoya, Carolyn Cabrera, Joaquin J. Jimenez
- 6558Selenium dependent regulation of immune checkpoint control in acute myeloid leukemiaDeborpita Sarkar, Fenghua Qian, Robert F. Paulson, K.Sandeep Prabhu
- 1365Regulation of ribosomal RNA synthesis in acute myeloid leukemia.Putzer J. Hung, Jill A. Henrich, Charles Antony, Vikram R. Paralkar
- 5302Defining the landscape of TP53 mutations in acute myeloid leukemiaJoseph Stenberg, Jordan Redemann, Jessica Lewis-Gonzalez, Rama Gullapalli et al.
- 5552MHC class II engager immunotherapy for the treatment of acute myeloid leukemiaLena Golick, Reeder Robinson, Leticia Reyes, Sandeep Gupta et al.
- 5678Cuproptosis induction in TP53-mutated acute myeloid leukemia.Yuju An, Xinghan Zeng, Brandy Perkins, Nour S. Naji et al.
- 3870Deep learning-powered morphological analysis of acute myeloid leukemia.Ezgi June Olgac, Meghan Burr, Minna Suvela, Daniela Mendoza-Ortiz et al.
- 1864G3BP1 knockdown sensitizes the acute myeloid leukemia cell line HL60 to venetoclax by inducing apoptosis.Naoko Hosono, Rie Nishi, Naoko Ida, Chantana Polprasert et al.
- 1862Targeting nucleolin overcomes MCL-1-mediated venetoclax resistance in acute myeloid leukemia.Kyung Jin Kim, Jihyun Um, Eun Jung Shin, Yu Mi Ji et al.
- 1269Silencing of ACACA sensitizes acute myeloid leukemia cells to venetoclax.Akansha Jalota, Anna Skwarska, Yen Bao Huynh, Fumiaki Sato et al.
- 3774Genomic landscape of acute myeloid leukemia in an African ancestry cohort: A pilot studyOluyemi Akinloye, Olayiwola Akianji Popoola, Olatunde Fakoya, Stella Rwazuala et al.
- 5967Overexpression of the transcription factor gene TGIF1 inhibits proliferation in NRAS-driven acute myeloid leukemia cellsMichael Roberts, Herryung Choi, Chase Mitchell Weizer, Helena Holley et al.
- 1854Selective Mcl-1 inhibition with KS18 overcomes apoptotic resistance and enhances FLT3-targeted therapy in acute myeloid leukemia.Sahil Jethi, Krishne Gowda, Tulin Budak-Alpdogan, Subash C. Jonnalagadda et al.
- LB354Pharmacologic TSC2 inhibition sensitizes acute myeloid leukemia to proteasome inhibition via mTORC1 mediated mitochondrial catastropheShakti Pattanayak, Boaz Tirosh, Omid Hajihassani, Jordan M. Winter et al.
- 5375Development of reference standards for clonal evolution and measurable residual disease in acute myeloid leukemia.Colt W. Nash, Matthew G. Butler, Ojaswee Dahal, Jayanthi Ramprakash et al.
- 4514Development and validation of a CyTOF assay for measuring phosphoproteins in AML blast cell populations in whole blood from AML patients.Steven R. Pirie-Shepherd, Crystal Tarrago, Wenxin Zheng, Sen Zhang et al.
- 5852A novel CD33 and TRAIL-R2 targeting bispecific antibody to treat relapsed/refractory acute myeloid leukemiaShiva Bhowmik, William Brady, Kaitlyn Ko, Sheng Cai et al.
- 4585A novel thioxanthenone activates p47phox to exploit redox vulnerabilities in acute myeloid leukemiaMadison Gamble, Claudia M. Espitia, Sruthi Sureshkumar, Natalie Hakim et al.
- 7897Novel Rho-GTPase regulatory protein gene family variants are frequent and associate with poor survival in patients (pts) with acute myeloid leukemia (AML)Ethan Hamp, Lorenz Oelschläger, Bailee N. Kain, Deedra Nicolet et al.
- 2809VIP/VPAC signaling as a phagocytosis checkpoint in TP53-mutated acute myeloid leukemiaZihan (Clarence) Chen, Tuisha Gupta, Fanyuan Zeng, Yujie Chen et al.
- 2808A first in class VIP receptor antagonist as an immunotherapeutic for acute myeloid leukemiaSwapnaa Balaji, Antonio Ward, Yuou Wang, Jian-Ming Li et al.
- 7727Integrated FHIT and IDH2 biomarkers predict synthetic lethal response to DCPS inhibition in acute myeloid leukemiaMadhurendra Singh, Francesca Grassi, Lisa Bast, Simon Moussaud et al.
- 1890Targeting ribonucleotide reductase to overcome FLT3 inhibitor resistance in acute myeloid leukemia.Zhen Tian, Peng Wang, Stacia Octaviani, Yahui Li et al.
- 145CD8 nanobody-targeted lipid nanoparticles encapsulating CD13 nanoCAR circular RNAs for in situ CAR-T cell eradication of acute myeloid leukemia.Wilson Huang, Diva Chen, Yun-Chin Chou, Tsung-Chih Chen et al.
- 5241Personalized fusion measurable residual disease detection in acute myeloid leukemia using droplet digital PCRAsra Noor, Xiaojuan Cao, Maggie J. Cox, Francesca Ferraro et al.
- 3496Epigenetic repurposing by CBFA2T3-GLIS2 reveals a druggable DNA methylation axis in high-risk pediatric AML vulnerability in pediatric AMLSamrat Roy Choudhury, Arundhati Chavan, Rhonda E. Ries, Giselle Almeida Gonzalez et al.
- 5399QLS2309, a trifunctional NKp46/CD16a-NK cell engager targeting CD70 enhances efficacy against acute myeloid leukemia via mitigating the refraction to therapeutic antibody-dependent cytotoxicity.Liuqing Yang, Ruimei Li, Xiaoran Wu, Shuyong Zhao et al.
- 7298Extracellular acidosis modulates calcium signaling and adaptive resistance mechanisms in acute myeloid leukemiaEva Gez, Sofia Titah, Aurélie Guillemette, Céline Berthon et al.
- 2439Predictive modeling of venetoclax/azacitidine response in acute myeloid leukemia using inflammatory cytokine profiling and clinical data from the NCT04267081 trial cohortAnkita Srivastava, Bahar Tercan, David L. Gibbs, Heikki Kuusanmäki et al.
- CT267Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes/neoplasmsDennise A. de Jesús-Díaz, Aaron Goldberg, Steve Abella, Caroline M. Robb et al.
- 1662GSPT1 degrader antibody conjugate, BLB-201, for the treatment of high-risk acute myeloid leukemiaRakesh Bam, Wenjian Qian, John Liu, Peipei Zheng et al.
- 5201Tuning gated CAR-T cells for enhanced activity against acute myeloid leukemiaShawn Barman, Molly Shields, Tatiana Fourfouris, Ki Jun Lee et al.
- 7301Effect of chronic exposure to acidic pH on the MOLM-13 acute myeloid leukemia cell lineAurélie Guillemette, Eva Gez, Sofia Titah, Céline Berthon et al.
- 2495Rapid clinical diagnostic classification and risk stratification in acute myelogenous leukemia (AML) using whole genome sequencing (WGS)Wayne M. Jepsen, Jonathan J. Keats, Sara A. Byron, Cherie Wesley et al.
- 5454Identification of microRNA clusters as predictors of chemotherapy response in acute myeloid leukemia.Ziang Chen, Jennifer Rangel Ambriz, Yu-Hsuan Fu, David Eugene Frankhouser et al.
- 6835Multiomic state-transition framework reveals chemotherapy-induced metabolic reprogramming in acute myeloid leukemia.Jennifer Rangel Ambriz, Ziang Chen, Yu-Hsuan Fu, David Eugene Frankhouser et al.
- 163Allogeneic double-negative T cells induce an innate-like cytotoxic function in CD8+T cells against acute myeloid leukemia.Leanne Palichuk, Enoch Tin, Pauline Douglas, Ruzena Filandrova et al.
- 4466Clinical-grade CK2 inhibitor CX-4945 synergistically enhances venetoclax-mediated antileukemic activity in preclinical acute myeloid leukemia models.Upendarrao Golla, Muhammad Danial, Rajesh Rajaiah, Marudhu Pandiyan Shanmugam et al.
- 5136Multi-targeted MNK inhibitors as anticancer agents for AMLSophie Derusha, Erika Lisabeth, Sonali Kurup
- 4056Preclinical evaluation and safety of CBX-250 in acute myeloid leukemia: A bispecific T cell engager targeting Cathepsin-G peptide/HLA complexJennifer Helble, Geraldine L. Paulus, Preethi Sankaran, Tanzila Rahman et al.
- 4530Synergistic targeting of Mediator complex and BCL-2 reveals a novel therapeutic strategy for acute myeloid leukemiaCamille Aitchedji, Céline Moison, Deanne Gracias, Rodrigo Mendoza-Sanchez et al.
- LB387Genome-wide association study identifies germline susceptibility loci for acute myeloid leukemiaXueyao Wu, Filip Pirsl, Gabrielle Schmidt, Maryam Rafati et al.
- 198The IL-33/ST2 signaling reshapes the immune landscape and promotes leukemia transformation in acute myeloid leukemia.Yu-Hsuan Fu, Man Li, Ying-Chieh Chen, Lianjun Zhang et al.
- 4260Deciphering the dysfunctional immunological synapse in acute myeloid leukemia through microfluidicSofia Titah, Clara Lewuillon, Faruk Azam Shaik, Aurelie Guillemette et al.
- 5199uPAR-targeting CAR-NK cells enhance cytotoxicity against acute myeloid leukemiaXingliang Guo, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva et al.
- 135Memory-like NK cell targeting to CD123 and CD33 improves killing of acute myeloid leukemia.Emily Phillips, Lyra Morina, Lynne Marsala, Wilbur Song et al.
- 3906Small-molecule inhibitors as salvage therapy for CBFB::MYH11-associated acute myeloid leukemia.Thuy An Nguyen, A S M Waliullah, Joshua Pei, Misha Padigala et al.
- 4513Structural surface protein targets for AML.James Dowell, Daniel Benjamin, Patric Sadecki, Jonathan Schmitz et al.
- 4468Anti-leukemic effects of WNK1 inhibition are enhanced by combination with ATRA in AML.Jordan D. Cress, Emily Katoni, Parameswaran Ramakrishnan
- 5666Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 levels in AML cell lines.Elizabeth C. Trull, Philip C. Amrein
- 7069Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged acute myeloid leukemia.Tulasigeri Totiger, Mina Tayari, Claudia Cabrera Pastrana, Florencio Munoz-Legarre et al.
- 3979Targeting nicotinamide metabolism with NAMPT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemiaMichelle Haber, Mawar Karsa, Patrick Connerty, Ayu Karsa et al.
- 5377Prediction of relapse risk in favorable outcome AML from DNA methylation data.Jamie Endicott, Ruslan Strogantsev, CRISTINA TOGNON, Hisham Mohammed et al.
- 1710ORM-1153: A novel CD123-targeting degrader antibody conjugate with proprietary GSPT1 degrading payload for the treatment of acute myeloid leukemiaDongki Choi, Adam Boutin, Jessica Alves, Sang Hyun Lee et al.
- 1843Venetoclax-resistant AML cell models as a platform for exploring new generation drug for BCL2 inhibitor resistance.Jinjin Wang, John Liu, Lin Teng
- 1709
- 1834A mathematical model for fitting adjusting azacytidine in AML or SMD patients.Quentin Gerbault, Loic Osanno, Joseph Ciccolini, Laure Farnault et al.
- 4469FACT Complex — A gatekeeper of differentiation in AML.Soumya Sharma, Sagarajit Mohanty, Stefan R. Sweha, Kazuya Fukasawa et al.
- 5938High-resolution multi-omic dissection of bone marrow in TP53-mutant acute myeloid leukemiaGonzalo Lopez Garcia, Felix Andreas Radtke, Sagnik Banerjee, BIJAY JAISWAL et al.
- ND10
- 1863Development and characterization of the venetoclax-resistant AML model to enable preclinical drug discovery.Jifan Yuan, Miaomiao Yu, Gaoxiang Liu, Jian Xiang et al.
- 4175Neoantigen-guided TCR discovery pipeline to improve specificity and reduce off-target toxicity in AMLPamella Borges, Martiela Freitas, Samee Ullah, Hussein A. Abbas et al.
- 7500Dependent lineage regulatory programs in TP53-mutated acute myeloid leukemia revealed through deep single-cell multi-omic profiling of patient samplesFelix A. Radtke, Bijay S. Jaiswal, Gonzalo Lopez, Junfei Zhao et al.
- 5301Evaluating the molecular landscape of genetic mutations among Black patients with acute myeloid leukemiaEno-obong B. Udoh, Xiaoying (Nicole) Chen, Sarah J. Philip, Yazeed Sawalha et al.
- 5752Bi-functional thiopurine-based oligonucleotides for AML cell-targeted telomere damage and immunostimulationChunsong Yu, Elaine Y. Kang, Piotr Swiderski, Haiqing Li et al.
- 7162CD180-targeting ADCs with a topoisomerase I inhibitor payload achieve strong efficacy in AML tumorsGarima Kaushik, Marina Bell, Bandana Vishwakarama, Abdul Mondal et al.
- 55Differentiation state and immune interaction contribute to drug response in AML.Natasha R. Black, Trevor Enright, Mira Rajagopalan, Melissa Stewart et al.
- 3273The mitochondrial protease YME1L regulates type 1 interferon signaling via the STING pathway in AMLYihe Zhang, Geethu Thomas, Rose Hurren, Yongran Yan et al.
- 6908Large-scale patient cohorts integration via a novel Bayesian transfer learning framework identifies robust drug response signatures in AML.Dharani Thirumalaisamy, Evan F. Lind, Elie Traer, Jeffrey W. Tyner et al.
- 7413CD36 influences leukemia progression in MLL-AF9-driven AML by modulating the leukemia immune microenvironmentYiting Meng, Wenda Zhu, Mateusz Pospiech, Long Huynh et al.
- 7107Dual FLT3/BRAF inhibitor PHI3 overcomes RAS-driven resistance in FLT3-mutant AMLShikhar Sharma, Anna Skwarska, Evangelia Matenoglou, Sovira Chaudhry et al.
- 4280Restoration of LAT signaling via the ALA-CART platform promotes metabolic resiliency and persistence of AML CAR T cellsCatherine Danis, Amanda J. Novak, Etienne Danis, Angie Vazquez et al.
- 7784Targeting PRMT7 elicits anti-AML immunity by promoting MHC-I expressionShuaishuai Ge, Kaixiu Luo, Lei Zhang, Meng Liu et al.
- 133NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK therapy in AML.Joseph A. Clara, Nile Liu, Mala Chakraborty, Kwong Y. Tsang et al.
- 3403High content imaging of patient cells to identify CLL and AML patient cohorts that predict drug responsesDavid W. Andrews, Mark X. Li, Alla Buzina, Glauber C. Brito et al.
- 4515Clinically relevant AML modeling with in vitro bone marrow niche and in vivo PDX approaches.Talita Stessuk, Hanna Vermeer, Afsaneh Golestani, Jolie Flach et al.
- 1962Epigenetic remodeling of BCOR-PRC1.1 complex dictates response and resistance to IDH inhibitors in AML.Sarah Hanache, Xiaoyan Zhang, Satoko Ogata, Hidetaka Uryu et al.
- 5140Development of hydrophilic and metabolically stable heterocyclic AOH1996 analogues for pediatric AML oral liquid formulationsPouya Haratipour, Melissa Valerio, Michaela R. Jacobs, Maryam Zangi et al.
- 4511Dual targeting of IKKβ and NR4A1 for AML therapy.Chandra Kumar Maharjan, Yi Liu, Yufeng Xiao, Bristy Podder et al.
- 5872CLK inhibitor BH-30236 synergizes with venetoclax in anti-leukemia activity via splicing modulation in preclinical AML and CLL modelsWei Deng, Ping Jiang, Zhenping Wang, Yue Hu et al.
- 2188Integrative transcriptomic profiling and flow cytometry analysis of AML PDX models identify purine-pyrimidine metabolic dependency shared in LSCs and blasts.Kangsan Kim, Haiming Xu, Geoff Nelson, Tim Nieuwenhuis et al.
- 6490MEK inhibition overcomes stromal-mediated resistance to a MERTK targeted therapy in AML co-cultures and vascularized mesenchymal organoidsChloe Hope, Katherine Minson, Eleana Vasileiadi, Madeline G. Higgins et al.
- 1876Pre-treatment with azacytidine sensitizes RAS mutated secondary AML to the pan-RAS inhibitor RMC-7977.Xinghan Zeng, Yuju An, Brandy Perkins, Tessa Seale et al.
- 3896MERTK inhibitor MRX-2843 sensitizes AML to venetoclax and azacitidine in preclinical models.Aashis Thapa, Chloe Hope, Edward B. Henderson, Austre Y. Schiaffino Bustamante et al.
- 3749Integrative multiomics and functional studies to identify biomarkers of AOH1996 sensitivity across AML subtypesHamsini Kala, Dana Abou Abbas, Robert J. Hickey, Linda H. Malkas et al.
- 5827Actimab-A, a CD33-targeted actinium-225 radioconjugate, drives mutation-agnostic anti-leukemic activity and synergizes with standard therapies in AML through transcriptional reprogrammingAmanda S. Chin, Merve Sahin, Jason Li, Le-Cun Xu et al.
- 5868Proteomic analysis and efficacy evaluation reveal strong synergistic anti-leukemic activity of lasmotinib combined with menin inhibitors for AMLAn-Na Moon, Hee-sun Hwang, Ky-Youb Nam, KyungMin Cha et al.
- 5300Clinical utility of whole genome sequencing for upfront risk stratification in AML and MDS patientsKerry D. Fitzgerald, Dennis D. Krutkin, Jenny Brouckaert, Traci Pawlowski et al.
- 2440Single-cell MRD profiling identifies CXCR4-high AML as a responder population to CXCR4 inhibition with MotixafortideEnise Ceran, Sonia Jaramillo-Segura, Anne Kahtrin Merbach, Christian Rohde et al.